Shouman Wang
YOU?
Author Swipe
View article: Prognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer
Prognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer Open
The baseline neutrophil-to-lymphocyte ratio (NLR) has been linked to HER2-positive breast cancer (BC) prognosis treated with trastuzumab in previous reports. Here, the prognostic and predictive utility of baseline NLR in relation to trastu…
View article: Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial Open
Neoadjuvant T-DXd-THP demonstrated statistically significant and clinically meaningful pCR benefit and improved safety versus ddAC-THP.
View article: Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study
Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study Open
Background: To evaluate the efficacy and safety of a chemotherapy-free regimen consisting of monoclonal antibody trastuzumab, tyrosine kinase inhibitor pyrotinib and CDK4/6 inhibitor dalpiciclib in patients with hormone receptor-negative/H…
View article: Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study
Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study Open
Background: Despite significant advancements in treatment, patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) continue to face the challenge of drug resistance, highlighting the need to de…
View article: NSUN2–tRNAVal−CAC-axis-regulated codon-biased translation drives triple-negative breast cancer glycolysis and progression
NSUN2–tRNAVal−CAC-axis-regulated codon-biased translation drives triple-negative breast cancer glycolysis and progression Open
View article: UBR5 antagonizes DNA damage to enhance the doxorubicin resistance of triple-negative breast cancer by p38 signaling
UBR5 antagonizes DNA damage to enhance the doxorubicin resistance of triple-negative breast cancer by p38 signaling Open
Background: Triple-negative breast cancer (TNBC) is characterized by aggressive behavior and limited treatment options, with chemotherapy resistance posing a significant clinical challenge. UBR5, an E3 ubiquitin ligase, has been consistent…
View article: BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study Open
View article: Long-Term Efficacy and Safety of Anti-HER2 Antibody-Drug Conjugate SHR-A1811 in Heavily Treated HER2-Expressing or Mutated Advanced Solid Tumours: A Global Phase 1 Trial (HORIZON-X)
Long-Term Efficacy and Safety of Anti-HER2 Antibody-Drug Conjugate SHR-A1811 in Heavily Treated HER2-Expressing or Mutated Advanced Solid Tumours: A Global Phase 1 Trial (HORIZON-X) Open
View article: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer Open
Importance Preferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed de…
View article: Data from Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Data from Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data Open
Purpose:Patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-…
View article: Supplementary Figure 1 from Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Supplementary Figure 1 from Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data Open
Survival analysis according to treatment line, hormone receptor status and metastatic sites.
View article: Supplementary Legend from Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Supplementary Legend from Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data Open
Supplementary Legend
View article: Vasculogenic Mimicry Related Long Noncoding RNA Signature Reveals New Therapy Strategy in Breast Cancer
Vasculogenic Mimicry Related Long Noncoding RNA Signature Reveals New Therapy Strategy in Breast Cancer Open
Background Vasculogenic mimicry (VM) is linked closely to the tumorigenesis. However, VM-related lncRNAs (VRLs) involved in the mediation of breast cancer (BC) are still unknown. This research aimed to identify a prognostic signature of VR…
View article: Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study
Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study Open
Objective Hormone receptor (HR)-low/HER2-negative breast cancers (BCs) are more likely to be basal-like BCs, with similar molecular features and gene expression profiles to HR-negative (estrogen receptor <1% or negative and progesterone…
View article: Research progress on the multi-omics and survival status of circulating tumor cells
Research progress on the multi-omics and survival status of circulating tumor cells Open
View article: Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial
Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial Open
Purpose This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Experimental design Data from 780 pati…
View article: METTL3-mediated m<sup>6</sup>A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis
METTL3-mediated m<sup>6</sup>A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis Open
Doxorubicin (DOX) resistance in breast cancer (BC) poses a huge challenge for the therapeutic effect on BC. Lnc KCNQ1OT1 play crucial roles in chemotherapy resistance. However, the role and mechanism of lnc KCNQ1OT1 in DOX resistance BC ha…
View article: METTL3-mediated m <sup>6</sup> A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis
METTL3-mediated m <sup>6</sup> A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis Open
Doxorubicin (DOX) resistance in breast cancer (BC) poses a huge challenge for the therapeutic effect on BC. Lnc KCNQ1OT1 play crucial roles in chemotherapy resistance. However, the role and mechanism of lnc KCNQ1OT1 in DOX resistance BC ha…
View article: A pilot study on pyroptosis related genes in peripheral blood mononuclear cells of non-small cell lung cancer patients
A pilot study on pyroptosis related genes in peripheral blood mononuclear cells of non-small cell lung cancer patients Open
Objective To investigate the GSDMD, CASP1, CASP4 and CASP5 expression in peripheral blood mononuclear cells of non-small cell lung cancer patients and analyze their clinical significance. Methods 71 non-small cell lung cancer patients were…
View article: Validation of reference genes for the normalization of the RT-qPCR in peripheral blood mononuclear cells of septic patients
Validation of reference genes for the normalization of the RT-qPCR in peripheral blood mononuclear cells of septic patients Open
Our first systematic analysis of the reference genes in PBMC of septic patients suggested YWHAZ was the best candidate. The combination of ACTB, PKG1 and YWHAZ could improve RT-qPCR accuracy in septic patients. Our results identified the m…
View article: Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study Open
View article: Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study
Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study Open
Our study confirmed the benefit of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy on pCR with a tolerable safety profile in routine clinical practice in Chinese patients with HER2-positive BC. HR-negativity and Ki…
View article: Stabilization of estrogen receptor α by <scp>USP37</scp> contributes to the progression of breast cancer
Stabilization of estrogen receptor α by <span>USP37</span> contributes to the progression of breast cancer Open
Breast cancer is a major cause of cancer‐related morbidity and mortality in women. Estrogen receptor‐positive breast cancer accounts for roughly 70%‐80% of breast tumors, and estrogen receptor alpha (ERα) has been considered as a key drive…
View article: Validation of reference genes for the normalization of the RT- qPCR in peripheral blood mononuclear cells of septic patients
Validation of reference genes for the normalization of the RT- qPCR in peripheral blood mononuclear cells of septic patients Open
Objective To screen and validate reference genes suitable for gene mRNA expression study in peripheral blood mononuclear cells (PBMCs) between septic patients and healthy controls (HC). Methods Total RNA in PBMCs was extracted and RT-qPCR …
View article: Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer. Open
SII has important clinical significance in predicting the efficacy and prognosis of NAC in TNBC patients, and it has the potential to be a biomarker.
View article: The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study Open
Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited.…
View article: Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data Open
Purpose: Patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world data…
View article: A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report
A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report Open
View article: Conventional suture with prolonged timing of drainage is as good as quilting suture in preventing seroma formation at pectoral area after mastectomy
Conventional suture with prolonged timing of drainage is as good as quilting suture in preventing seroma formation at pectoral area after mastectomy Open
View article: Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis Open
[This corrects the article DOI: 10.3389/fonc.2020.00811.].